April 12, 2021, Baltimore, Maryland – NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: US 10.967,007 B2 “Cardiac Stem Cells for Cardiac Repair”. The innovation was developed by Dr. Sunjay Kaushal, a pediatric cardiac surgeon, while he was at the University of Maryland, Baltimore and NeoProgen is the exclusive licensee of the newly issued patent. [Read more…]
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19
Golden, Colorado-April 6, 2021 — Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Our Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19. [Read more…]
5 Reasons to Use Biological Industries’ NutriStem® for Isolation and Growth of hMSCs
Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells present in a variety of tissue niches within the human body. As multipotent cells, they can differentiate into a range of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. [Read more…]
Cytonome cell sorter aids in Parkinson’s treatment
April 6, 2021, BEDFORD, Mass. — Cell sorting technology leader and innovator Cytonome-ST, LLC, has assisted pharmaceutical firm Sumitomo Dainippon Pharma Co., Ltd. to produce enough human stem cells to proceed with a clinical trial of a new treatment aimed at curing Parkinson’s Disease. [Read more…]
Century Therapeutics Raises $160M for iPSC-derived CAR-T and CAR-NK Cell Therapeutics
In early March, Century Therapeutics made waves by raising $160 million in Series C financing. This was on top of the existing $250 million that the company raised during a Series A round in 2019, bringing its total financing to an astounding $410 million. The Series C financing round was led by Casdin Capital, a New York-based investment firm that targets life science and healthcare companies. [Read more…]
- « Previous Page
- 1
- …
- 172
- 173
- 174
- 175
- 176
- …
- 339
- Next Page »